Please login to the form below

Not currently logged in

Vaccine nationalism must be prevented, says WHO director-general

Tedros Adhanom Ghebreyesus warns against supply nationalism

World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus has warned against vaccine nationalism, as countries across the world secure early access to promising COVID-19 vaccines.

In an address made yesterday, the WHO director-general called on all countries to work collectively to end the pandemic, by sharing finites supplies “strategically and globally”.

“No one country has access to research and development, manufacturing and all the supply chains for all essential medicines and materials,” said Ghebreyesus.

“And if we can work together, we can ensure that all essential workers are protected and proven treatments like dexamethasone are available to those who need them,” he added.

Ghebreyesus encouraged countries to take into account the WHO’s recommendation for equitable allocation of COVID-19 vaccines, with doses to be given proportionally to all countries participating in its ACT-Accelerator.

The WHO also recommends that consideration should be given to countries in relation to threat and vulnerability, with front-line health and social care workers also due to be given priority.

“If we don't protect these highest risk people from the virus everywhere and at the same time, we can't stabilise health systems and rebuild the global economy,” said Ghebreyesus.

A number of countries have already begun to secure doses of a myriad of potential COVID-19 vaccine candidates, including the US, UK and European Union.

In the US, the government is aiming to deliver 300 million doses of a safe and effective COVID-19 vaccine to the American people by January 2021 under its Operation Warp Speed initiative.

This includes deals made to advance and secure doses of vaccines being developed by Johnson & Johnson, AstraZeneca/Oxford University, Pfizer/BioNTech, Moderna, Novavax and more.

The UK has also secured access to six different vaccine candidates as part of the government’s strategy to build a portfolio of promising COVID-19 vaccines.

This includes securing 60 million doses of Novavax’s vaccine candidate and 30 million doses of J&J’s shot.

Ghebreyesus also encouraged all member states to join the COVAX Global Vaccines Facility, a mechanism designed to ensure joint procurement and pooling risk across multiple vaccine candidates.

“As we accelerate the science, solidarity is needed to provide a joint solution to the pandemic,” added Ghebreyesus.

Article by
Lucy Parsons

19th August 2020

From: Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...